Skip to content
DataLookout
Menu

Symbiotic-LungNCT07226999

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2/3
SponsorPfizer
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 6 more changesShow less
    • Eligibility criteria expanded, about 90 words
    • Trial sites expanded: 82 → 85 locations
    • Interventions modified
    • Trial arms changed: 3 → 5
    • Secondary endpoints: 14 to 15
    • Study title expanded, about 7 words
  2. Notable Eligibility criteria expanded, about 11 words
    • Primary endpoints: details revised at 1 of 3 entries
    • Study sites: 83 to 82
    • Secondary endpoints: details revised at 2 of 14 entries
  3. Minor Trial sites expanded: 73 → 83 locationsv8
  4. Minor Trial sites expanded: 49 → 73 locationsv7
  5. Minor Trial sites expanded: 43 → 49 locationsv6
  6. Minor Trial sites expanded: 32 → 43 locationsv5
  7. Minor Trial sites expanded: 26 → 32 locationsv4
  8. Minor Trial sites expanded: 6 → 26 locations
    • Secondary endpoints: details revised at 2 of 14 entries
    • Study title expanded, about 1 word
    v3
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 6
    • Start date changed from estimate of Nov 17, 2025 to Dec 9, 2025
    v2
  10. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 2: Number of participants with treatment-emergent adverse events
Timeframe: Up to 90 days after the last dose of treatment
Phase 3: Overall Survival (OS)
Timeframe: Up to approximately 2 years after completion of study treatment of last study participant

Secondary (15)

Confirmed ORR using RECIST v1.1 as assessed by investigator
Duration of Response (DOR) as assessed by Investigator based on RECIST v1.1
Progression Free Survival (PFS) as assessed by investigator based on RECIST v1.1
Number of participants with Laboratory abnormalities
Phase 2: Number of Participants who Experience a Dose-Limiting Toxicity (DLT)
Show 10 moreShow less
Phase 2: Overall Survival
Phase 3: PFS using RECIST v1.1 as assessed by blinded independent central review (BICR)
Phase 3: Confirmed ORR using RECIST v1.1 as assessed by BICR
Phase 3: DOR using RECIST v1.1 as assessed by BICR
Incidence of antidrug antibody against PF-08634404
Pharmacokinetics: Serum concentrations of PF-08634404
Phase 3: Mean scores and Change from baseline in the global health status/quality of life (QoL), function, and symptom scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Phase 3: Mean scores and Change from Baseline on the EORTC Quality of Life Cancer Questionnaire - Lung Cancer 13 (EORTC QLQ-LC13)
Phase 3: Time to definitive deterioration (TTdD) in the global health status/QoL, function, and symptom scores on the EORTC QLQ-C30
Phase 3: TTdD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13

Arms and interventions

Phase 2 Part A - Chemo Combo ArmExperimental

Participants will receive PF-08634404 in combination with chemotherapy

Phase 2 Part B - Doublet ArmExperimental

Participants will receive PF-08634404 in combination with tarlatamab

Phase 2 Part B - Triplet ArmExperimental

Participants will receive PF-08634404 in combination with tarlatamab and chemotherapy.

Phase 3 Experimental ArmExperimental

Participants will receive PF-08634404 in combination with chemotherapy

Phase 3 Control ArmActive comparator

Participants will receive atezolizumab in combination with chemotherapy

Drugs: PF-08634404, Tarlatamab, Chemotherapy, Atezolizumab

Sites

85 sites in 10 countries

United States 55, Spain 7, Japan 4, Puerto Rico 4, Australia 3, Italy 3, Taiwan 3, China 2, France 2, Germany 2